Tharimmune Inc. (THAR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tharimmune Inc. (THAR) has a cash flow conversion efficiency ratio of -0.026x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.44 Million) by net assets ($397.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Tharimmune Inc. (THAR) shareholders funds for net asset value and shareholders' equity analysis.
Tharimmune Inc. - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Tharimmune Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tharimmune Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tharimmune Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GREENLAND RESOURCES INC.
F:M0LY
|
-0.139x |
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
-0.376x |
|
CB Industrial Product Holding
KLSE:7076
|
-0.022x |
|
Hardwyn India Limited
NSE:HARDWYN
|
0.001x |
|
Avatec Co. Ltd
KQ:149950
|
0.021x |
|
Bastogi S.p.A
F:BAOA
|
0.002x |
|
Horizon Copper Corp.
V:HCU
|
-0.023x |
|
Tecogen Inc.
NYSE:TGEN
|
-0.120x |
Annual Cash Flow Conversion Efficiency for Tharimmune Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Tharimmune Inc. from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see THAR stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $397.93 Million | $-16.13 Million | -0.041x | +99.51% |
| 2024-12-31 | $1.31 Million | $-10.90 Million | -8.337x | -942.85% |
| 2023-12-31 | $9.13 Million | $-7.30 Million | -0.799x | +32.42% |
| 2022-12-31 | $5.54 Million | $-6.56 Million | -1.183x | -610.21% |
| 2021-12-31 | $-4.68 Million | $-1.09 Million | 0.232x | -20.07% |
| 2020-12-31 | $-3.72 Million | $-1.08 Million | 0.290x | -33.35% |
| 2019-12-31 | $-1.62 Million | $-706.11K | 0.435x | -- |
About Tharimmune Inc.
Tharimmune, Inc. focuses on leveraging Canton Coin and supporting the Canton network to advance institutional blockchain adoption and the digitization of financial markets. It is also involved in the clinical-stage biotech research and development activities. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. w… Read more